SEC
MYGN icon

Seven Eight Capital’s Myriad Genetics MYGN Stock Holding History

Seven Eight Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,960
Closed -$821K – 406
2024
Q3 		$821K Buy
29,960
+20,298
+210% +$549K 0.07% 453
2024
Q2 		$236K Buy
+9,662
New +$212K 0.02% 642
2019
Q1 		– Sell
-70,061
Closed -$2.04M – 666
2018
Q4 		$2.04M Buy
70,061
+37,895
+118% +$1.36M 0.11% 232
2018
Q3 		$1.48M Buy
+32,166
New +$1.43M 0.09% 300
2017
Q4 		– Sell
-58,500
Closed -$2.12M – 533
2017
Q3 		$2.12M Buy
+58,500
New +$1.67M 0.26% 129
2016
Q3 		– Sell
-11,500
Closed -$352K – 474
2016
Q2 		$352K Buy
11,500
+10,700
+1,338% +$372K 0.12% 239
2016
Q1 		$30K Sell
800
-800
-50% -$30.1K 0.01% 464
2015
Q4 		$69K Buy
+1,600
New +$67.6K 0.05% 406
2015
Q1 		– Sell
-1,800
Closed -$61K – 619
2014
Q4 		$61K Buy
1,800
+1,406
+357% +$49.9K 0.1% 246
2014
Q3 		$15.2K Sell
394
-1,689
-81% -$63K 0.01% 465
2014
Q2 		$81K Buy
+2,083
New +$77.5K 0.08% 320
2014
Q1 		– Sell
-1,200
Closed -$25K – 427
2013
Q4 		$25K Buy
+1,200
New +$30.3K 0.03% 477

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Seven Eight Capital's MYGN Position: Q4 2024 in Review

Seven Eight Capital sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 29,960 shares — an estimated $821K sold.

Seven Eight Capital first reported a position in MYGN in Q4 2013 and held it in 12 quarters. The position peaked at $2.12M in Q3 2017. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • Seven Eight Capital reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 29,960 Myriad Genetics shares in Q4 2024, an estimated $821K.
  • Seven Eight Capital first reported a position in Myriad Genetics in Q4 2013 and held it in 12 quarters.
  • Seven Eight Capital's Myriad Genetics position peaked at $2.12M in Q3 2017.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.